These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36051360)

  • 61. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
    Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
    Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.
    Amadori S; Suciu S; Selleslag D; Aversa F; Gaidano G; Musso M; Annino L; Venditti A; Voso MT; Mazzone C; Magro D; De Fabritiis P; Muus P; Alimena G; Mancini M; Hagemeijer A; Paoloni F; Vignetti M; Fazi P; Meert L; Ramadan SM; Willemze R; de Witte T; Baron F
    J Clin Oncol; 2016 Mar; 34(9):972-9. PubMed ID: 26811524
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gemtuzumab ozogamicin in acute myeloid leukemia revisited.
    Thol F; Schlenk RF
    Expert Opin Biol Ther; 2014 Aug; 14(8):1185-95. PubMed ID: 24865510
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
    ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
    Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
    Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
    Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
    Olombel G; Guerin E; Guy J; Perrot JY; Dumezy F; de Labarthe A; Bastie JN; Legrand O; Raffoux E; Plesa A; Wagner-Ballon O; Cornet E; Salaun V; Preudhomme C; Thomas X; Pautas C; Chantepie S; Turlure P; Castaigne S; Dombret H; Feuillard J
    Blood; 2016 Apr; 127(17):2157-60. PubMed ID: 26929274
    [No Abstract]   [Full Text] [Related]  

  • 67. Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin.
    McNeil MJ; Parisi MT; Hijiya N; Meshinchi S; Cooper T; Tarlock K
    J Pediatr Hematol Oncol; 2019 Apr; 41(3):e174-e176. PubMed ID: 29734213
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients].
    Sakamaki H
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1629-34. PubMed ID: 18799927
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
    O'Hear C; Inaba H; Pounds S; Shi L; Dahl G; Bowman WP; Taub JW; Pui CH; Ribeiro RC; Coustan-Smith E; Campana D; Rubnitz JE
    Cancer; 2013 Nov; 119(22):4036-43. PubMed ID: 24006085
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
    Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
    J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The role of gemtuzumab ozogamicin in acute leukaemia therapy.
    Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM
    Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.
    van der Velden VH; Boeckx N; Jedema I; te Marvelde JG; Hoogeveen PG; Boogaerts M; van Dongen JJ
    Leukemia; 2004 May; 18(5):983-8. PubMed ID: 15029214
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
    Iacobucci I; Lonetti A; Candoni A; Sazzini M; Papayannidis C; Formica S; Ottaviani E; Ferrari A; Michelutti A; Simeone E; Astolfi A; Abbenante MC; Parisi S; Cattina F; Malagola M; Russo D; Damiani D; Gherlinzoni F; Gottardi M; Baccarani M; Fanin R; Martinelli G
    Pharmacogenomics J; 2013 Aug; 13(4):335-41. PubMed ID: 22584460
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
    Walter RB; Raden BW; Kamikura DM; Cooper JA; Bernstein ID
    Blood; 2005 Feb; 105(3):1295-302. PubMed ID: 15454492
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.
    Montesinos P; Kota V; Brandwein J; Bousset P; Benner RJ; Vandendries E; Chen Y; McMullin MF
    Cancer Chemother Pharmacol; 2023 May; 91(5):441-446. PubMed ID: 36892676
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
    Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
    Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy.
    Cairoli R; Furneri G; Di Virgilio R; Veggia B; Ferrara F
    BMC Health Serv Res; 2023 Jan; 23(1):36. PubMed ID: 36642712
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML.
    Sayar D; Burstein Y; Bielorai B; Toren A; Dvir R
    Pediatr Blood Cancer; 2010 Jul; 55(1):183-5. PubMed ID: 20310000
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient].
    Ogura K; Machida T; Nara M; Mayama K; Akagi T; Kubo K
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1881-3. PubMed ID: 18030030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.